Table 3. Univariate Analyses for Patients With Primary Hypercoagulable States and No HIT Compared to Patients With Primary Hypercoagulable States and HIT.
| Variable | Patients with primary hypercoagulable states and no HIT (N = 416) | Patients with primary hypercoagulable states and HIT (N = 416) | P value |
|---|---|---|---|
| Age | 53.4 ± 16.6 | 53.4 ± 16.6 | 1.000 |
| Gender - female | 248 (59.6%) | 248 (59.6%) | 1.000 |
| Obesity | 66 (15.9%) | 75 (18.0%) | 0.460 |
| Solid tumor without metastases | 4 (1.0%) | 12 (2.9%) | 0.074 |
| Metastatic cancer | 10 (2.4%) | 17 (4.1%) | 0.240 |
| Lymphoma | 6 (1.4%) | 3 (0.7%) | 0.505 |
| Uncomplicated diabetes | 70 (16.8%) | 89 (21.4%) | 0.112 |
| Diabetes with chronic complications | 13 (3.1%) | 28 (6.7%) | 0.024* |
| Drug abuse | 21 (5.0%) | 19 (4.6%) | 0.872 |
| Renal failure | 45 (10.8%) | 123 (29.6%) | < 0.0005* |
| AIDS | 0.0 (0.0%) | 0.0 (0.0%) | N/A |
| Major surgery | 119 (28.6%) | 161 (38.7%) | 0.003* |
| Congestive heart failure | 15 (3.6%) | 64 (15.4%) | < 0.0005* |
| Autoimmune disease (SLE, RA) | 46 (11.1%) | 78 (18.8%) | 0.002* |
*P < 0.05 statistically significant. HIT: heparin-induced thrombocytopenia; AIDS: acquired immunodeficiency syndrome; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis.